Qualigen Therapeutics, Inc. – NASDAQ:QLGN
Qualigen Therapeutics stock price today
Qualigen Therapeutics stock price monthly change
Qualigen Therapeutics stock price quarterly change
Qualigen Therapeutics stock price yearly change
Qualigen Therapeutics key metrics
Market Cap | 2.93M |
Enterprise value | N/A |
P/E | -0.2 |
EV/Sales | -0.09 |
EV/EBITDA | 0.04 |
Price/Sales | 0.57 |
Price/Book | 0.28 |
PEG ratio | N/A |
EPS | -2.21 |
Revenue | N/A |
EBITDA | -10.14M |
Income | -11.62M |
Revenue Q/Q | -100% |
Revenue Y/Y | 63.07% |
Profit margin | -226.32% |
Oper. margin | -296.26% |
Gross margin | 23.28% |
EBIT margin | -296.26% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeQualigen Therapeutics stock price history
Qualigen Therapeutics stock forecast
Qualigen Therapeutics financial statements
| Jun 2023 | 1.62M | -3.46M | -212.92% |
|---|---|---|---|
| Sep 2023 | 7.94M | -3.65M | -46.03% |
| Dec 2023 | 0 | -2.46M | |
| Mar 2024 | 0 | -2.03M |
| 2025 | 0 | -11.4M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-04-03 | -1.4 | -1.5 |
|---|
| Jun 2023 | 13149572 | 9.84M | 74.84% |
|---|---|---|---|
| Sep 2023 | 4316060 | 5.95M | 138.01% |
| Dec 2023 | 2033248 | 4.13M | 203.46% |
| Mar 2024 | 1003211 | 4.52M | 451.04% |
| Jun 2023 | -2.92M | -48.40K | -1 |
|---|---|---|---|
| Sep 2023 | 929.73K | 4.22M | -440K |
| Dec 2023 | -5.67M | 235.40K | -110K |
| Mar 2024 | -783.58K | 0 | 475K |
Qualigen Therapeutics alternative data
| Aug 2023 | 31 |
|---|---|
| Sep 2023 | 31 |
| Oct 2023 | 31 |
| Nov 2023 | 31 |
| Dec 2023 | 31 |
| Jan 2024 | 31 |
| Feb 2024 | 31 |
| Mar 2024 | 31 |
| Apr 2024 | 31 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Qualigen Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 8000 | 0 |
| Jun 2022 | 60000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | POIRIER MICHAEL S. director, officer.. | Common Stock | 30,000 | $0.57 | $17,100 | ||
Purchase | BROIDRICK AMY S. director, officer.. | Common Stock | 30,000 | $0.62 | $18,600 | ||
Purchase | KRUGER KURT H director | Common Stock | 8,000 | $1.22 | $9,760 | ||
Purchase | BROIDRICK AMY S. director, officer.. | Common Stock | 4,500 | $2.03 | $9,135 | ||
Purchase | POIRIER MICHAEL S. director, officer.. | Common Stock | 11,005 | $1.8 | $19,809 | ||
Purchase | LOTZ CHRISTOPHER L. officer: Vice Pre.. | Common Stock | 2,700 | $1.86 | $5,022 | ||
Purchase | KRUGER KURT H director | Common Stock | 4,000 | N/A | N/A | ||
Purchase | KRUGER KURT H director | Common Stock | 4,600 | N/A | N/A | ||
Purchase | KRUGER KURT H director | Common Stock | 1,400 | N/A | N/A | ||
Sale | DOYLE NOAH director | Common Stock | 500,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2021 18 Aug 2020 | Q1 2021 Earnings Call Transcript |
-
What's the price of Qualigen Therapeutics stock today?
One share of Qualigen Therapeutics stock can currently be purchased for approximately $1.9.
-
When is Qualigen Therapeutics's next earnings date?
Unfortunately, Qualigen Therapeutics's (QLGN) next earnings date is currently unknown.
-
Does Qualigen Therapeutics pay dividends?
No, Qualigen Therapeutics does not pay dividends.
-
How much money does Qualigen Therapeutics make?
Qualigen Therapeutics has a market capitalization of 2.93M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.44% to 5.2M US dollars. Qualigen Therapeutics made a loss 13.42M US dollars in net income (profit) last year or -$1.5 on an earnings per share basis.
-
What is Qualigen Therapeutics's stock symbol?
Qualigen Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "QLGN".
-
What is Qualigen Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Qualigen Therapeutics?
Shares of Qualigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Qualigen Therapeutics's key executives?
Qualigen Therapeutics's management team includes the following people:
- Mr. Michael S. Poirier Chairman & Chief Executive Officer(age: 69, pay: $639,970)
- Mr. Christopher L. Lotz Vice President of Fin. & Chief Financial Officer(age: 60, pay: $578,550)
- Mr. Shishir K. Sinha Vice President, Chief Operating Officer & Corporation Sec.(age: 58, pay: $288,620)
- Dr. Wajdi Abdul-Ahad Vice President of R&D and Chief Scientific Officer(age: 72, pay: $262,460)
- Ms. Amy S. Broidrick Pres, Chief Strategy Officer & Director(age: 67, pay: $52,080)
-
How many employees does Qualigen Therapeutics have?
As Jul 2024, Qualigen Therapeutics employs 4 workers, which is 87% less then previous quarter.
-
When Qualigen Therapeutics went public?
Qualigen Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 23 Jun 2015.
-
What is Qualigen Therapeutics's official website?
The official website for Qualigen Therapeutics is qualigeninc.com.
-
Where are Qualigen Therapeutics's headquarters?
Qualigen Therapeutics is headquartered at 2042 Corte Del Nogal, Carlsbad, CA.
-
How can i contact Qualigen Therapeutics?
Qualigen Therapeutics's mailing address is 2042 Corte Del Nogal, Carlsbad, CA and company can be reached via phone at +7 609189165.
Qualigen Therapeutics company profile:
Qualigen Therapeutics, Inc.
qualigeninc.comNASDAQ
4
Biotechnology
Healthcare
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Carlsbad, CA 92011
CIK: 0001460702
ISIN: US74754R2022
CUSIP: 74754R103
